BioNTech is planning to price the two-shot regimen of the COVID-19 vaccine below “typical market rates” and would even differentiate pricing between regions or nations. The company is currently first in the race to disclose interim information from a large-scale trial showing a highly effective COVID-19 vaccine.
Pfizer and partner BioNTech announced that their vaccine against COVID-19 was 90% effective according to their phase 3 trials.
Chilean President Sebastian Piñera announced on Thursday morning that the nation’s health regulator had given full approval for clinical trials of the AstraZeneca COVID-9 vaccine.
Russian pharmaceutical company Pharmasyntez formally asked the Kremlin on Monday afternoon to allow it to produce a generic version of the American COVID-19 drug Remdesivir, despite a lacking a patent to do so.
Qatar has signed a deal with drugmaker Moderna to buy its potential COVID-19 vaccine once it is finally approved and released for global use. While there are no internationally approved vaccines yet, several are in advanced trials, including from Pfizer, Johnson & Johnson and Moderna.
The Peruvian government announced on Sunday that it refused to sign a COVID-9 vaccine purchase deal with AstraZeneca PLC because the company failed to provide sufficient information from its studies and offered minimal amounts of inoculations.
Shares of Gilead Sciences jumped 6 percent on Friday morning after United States authorities approved its antiviral drug remdesivir as the treatment for the COVID-19 virus in the country.
OxyContin maker Purdue Pharma agreed to plead guilty to criminal charges over its handling of its prescription opioid OxyContin on Wednesday afternoon, in a deal with United States prosecutors that sidestepped paying billions of dollars in penalties and stopped short of criminally charging the Sackler family owners.